A new formula consisting of the five-factor score and earliest vasculitis damage index at diagnosis for predicting poor outcomes of antineutrophil cytoplasmic antibody-associated vasculitis

一种由五因素评分和诊断时最早的血管炎损伤指数组成的新公式,用于预测抗中性粒细胞胞浆抗体相关性血管炎的不良预后

阅读:1

Abstract

BACKGROUND: This study aimed to investigate whether a new formula consisting of more than two antineutrophil cytoplasmic antibody-associated vasculitis (AAV)-specific indices at diagnosis could predict poor outcomes during follow-up in patients with AAV. METHODS: This study included 323 patients first diagnosed with AAV. AAV-specific indices included the Birmingham vasculitis activity score (BVAS), the five-factor score (FFS), and the earliest vasculitis damage index (eVDI). Poor outcomes included all-cause mortality, end-stage kidney disease (ESKD), cerebrovascular accident (CVA), and acute coronary syndrome (ACS). The four formulas were created by adding each index: BVAS + FFS + eVDI, BVAS + FFS, BVAS + eVDI, and FFS + eVDI. RESULTS: The median age was 61.0 years (36.2% men). Among the four formulas, FFS + eVDI at AAV diagnosis exhibited the highest area under the curves (AUCs) for all-cause mortality and ESKD in receiver operating characteristic curve analysis. When the optimal cut-off was determined as 4.5 for all-cause mortality and ESKD simultaneously, patients with FFS + eVDI ≥4.5 at AAV diagnosis exhibited significantly higher risks for both all-cause mortality and ESKD, and lower cumulative patients' and ESKD-free survival rates than those without. in multivariable Cox analyses with other variables at AAV diagnosis, FFS + eVDI at AAV diagnosis was proven to be an independent predictor for all-cause mortality and ESKD during follow-up in patients with AAV. CONCLUSION: This study demonstrated that a new formula consisting of FFS and eVDI at AAV diagnosis could effectively predict both all-cause mortality and ESKD during follow-up in patients with AAV.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。